Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Surg Oncol Clin N Am. 2019 Apr 5;28(3):447–464. doi: 10.1016/j.soc.2019.02.002

Table 4.

Ongoing ACT clinical trials in EOC

Agent Phase Target antigen Infused cells Patients Trial identifier
TIL II - short-term cultured autologous TIL Metastasis ovarian cancer
TIL I - Re-stimulated T cells Platinum-resistant high grade serous ovarian cancer
TCR I MAGE-A4 MAGE-A4 specific TCR gene transferred T lymphocytes HLA-A*24:02 positive MAGE-A4 expressing EOC
TCR I NY-ESO-1 NY-ESO-1 specific TCR gene transduced T lymphocytes HLA-A*02:01 or HLA-A*02:06 positive NY-ESO-1 expressing EOC
TCR I/II NY-ESO-1 NY-ESO-1 (C259) transduced autologous T cells Patients with HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1
TCR I NY-ESO-1 Anti-NY ESO-1 TCR-transduced T cells Patients with HLA-A2+NY-ESO-1-expressing tumor
CAR I/II mesothelin Anti-mesothelin CAR transduced PBL Metastatic or unresectable cancer that expresses mesothelin
CAR I mesothelin Anti-mesothelin CAR transduced T cells Refractory or relapsed mesothelin expressing tumor
CAR I MUC16 4H11-28z/fIL-12/EGFRt+ genetically-modified T cells EOC with MUC16ecto antigen expression
CAR I/II EGFR anti-EGFR-CAR transduced autologous T cells Chemotherapy resistant or relapsed EOC with EGFR expression
CAR I/II ErbB2/Her2 anti-HER-2-CAR transduced autologous T cells Chemotherapy resistant or relapsed EOC with Her2 expression
CAR I CD133 anti-CD133-CAR vector-transduced T cells Chemotherapy refractory or relapsed CD133-positive EoC